Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$425.8 million.

  • Day One Biopharmaceuticals' Change in Acquisitions & Divestments fell 45855.15% to -$425.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.5 million, marking a year-over-year decrease of 1306.94%. This contributed to the annual value of $314.5 million for FY2024, which is 4534.93% down from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Change in Acquisitions & Divestments stood at -$425.8 million, which was down 45855.15% from $264.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $264.8 million during Q2 2025, with a 5-year trough of -$425.8 million in Q3 2025.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $129.5 million (2023), whereas its average is $79.2 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Change in Acquisitions & Divestments soared by 75957.5% in 2023, and later crashed by 45855.15% in 2025.
  • Day One Biopharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $119.2 million in 2022, then increased by 8.7% to $129.5 million in 2023, then surged by 59.41% to $206.5 million in 2024, then tumbled by 306.21% to -$425.8 million in 2025.
  • Its Change in Acquisitions & Divestments was -$425.8 million in Q3 2025, compared to $264.8 million in Q2 2025 and $161.0 million in Q1 2025.